2025 Coalition Recommendations
Since the release of the Coalition for Reducing Bureaucracy in Clinical Trials Statement in 2020 as well as the Coalition Recommendations in 2021, the Coalition has continuously pushed for a better clinical trials landscape. During our efforts we have gathered input, observed challenges and had many discussions with different stakeholders and policy makers.
These learnings led us to develop the updated Coalition Recommendations which we call the Coalition Recommendations 2025 with the most important points to consider to date and suggestions on how we can reduce bureaucracy and improve routines and work within clinical trials.
Trunk article
Throughout the autumn of 2022, we diligently collected quotes derived from real-life observations of the bureaucratic challenges in clinical trials. This allowed us to critically review our progress and accomplishments, paving the way for strategic planning of the Coalition’s future endeavors. As a result, we have crafted a comprehensive trunk article that eloquently encapsulates the Coalition’s remarkable work, notable achievements, and the driving force behind its existence.
Kindly find the trunk article provided below and please feel free to share it widely, assisting us in raising awareness about the crucial work carried out by the Coalition for Reducing Bureaucracy in Clinical Trials.
Coalition Recommendations 2021
Since issuing the joint statement , the Coalition has developed a series of concrete and consensus-based recommendations for reducing administrative burdens in clinical trials, clustered around four main themes: Safety reporting, informed consent, regulatory guidelines, and harmonisation of requirements across the EU.
These recommendations reflect, first and foremost, the views and needs of investigators and patients, but have taken in as much as possible the views of regulators, sponsors, ethics committees and other stakeholders. Their willingness to engage in dialogue and join the search for realistic, pragmatic and broadly-supported solutions has been invaluable in enhancing the quality and relevance of these recommendations.
Statement
In September 2020 a broad cross-disciplinary coalition of medical societies and patient advocates issued the joint statement ‘Reducing bureaucracy in clinical trials: now is the time!’
The statement calls for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper. At stake are the quality of clinical trials, access to innovative treatments and, crucially, patient safety.
The Coalition calls on regulators, policymakers, sponsors, ethics committees and other stakeholders to collaborate to make sure regulatory guidelines, safety reporting requirements and informed consent procedures do not harm what they are meant to protect: clinical trial quality and patient safety.